Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
- Seikagaku Initiates PII Trial for SI-614 for Dry Eye in US
January 24, 2012
- Sosei Announces Collaboration with CEOLIA Pharma
January 24, 2012
- Wakamoto Pharmaceutical Withholds Joint Venture Plan with Major Taiwanese Generics Company
January 23, 2012
- Astellas to Transfer 3 Drugs to Choseido including Tathion
January 23, 2012
- Indications for Alveolar Pyorrhea Removed from Lysozyme HCl
January 23, 2012
- Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
- NPhA’s Iwasaki Says Strength in Securing Profit Weak
January 23, 2012
- GSK Obtains Approval for Paxil CR Tablets, to Comarket with DSP
January 20, 2012
- No. of Patients Not Recommended to Take Generics Down to 40%: Sawai Survey
January 20, 2012
- Teijin Pharma: Bonalon IV Infusion Approved as Japan’s 1st Once-a-Month IV Drug for Osteoporosis
January 20, 2012
- Takeda to Cut 2,800 Jobs in US, Europe by Integrating Operation Sites
January 19, 2012
- Takeda President Hasegawa Envisions Japanese National as Successor
January 19, 2012
- Takeda’s Next Core Product, Novel ARB Azilva Approved
January 19, 2012
- Senju Obtains Approval for Glaucoma Treatment Aiphagan
January 19, 2012
- Daiichi Sankyo to Copromote 1st Antibody Drug with AstraZeneca
January 19, 2012
- Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
- AZ Appeals Effectiveness of Faslodex as Secondary Treatment
January 18, 2012
- BTMU Forecast 1% Growth in 2012 Domestic Ethical Drug Market
January 18, 2012
- Hisamitsu Starts Capital, Business Alliance with Yutoku Following Acquisition of 15% of Its Shares
January 18, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…